LoValTech

LovalTech, founded in January 2022 during the COVID-19 pandemic, focuses on developing a French nasal vaccine designed to block the contagion of the virus. The company operates in the biotechnology and pharmaceutical industry, targeting healthcare providers, governments, and global health organizations. Its business model revolves around research and development, clinical trials, and eventual mass production and distribution of the vaccine. Revenue is generated through government contracts, partnerships with pharmaceutical companies, and direct sales to healthcare institutions. LovalTech aims to address the urgent need for effective COVID-19 prevention solutions, leveraging innovative nasal delivery methods to enhance vaccine efficacy and accessibility.

Keywords: nasal vaccine, COVID-19, biotechnology, pharmaceutical, healthcare, contagion prevention, clinical trials, mass production, government contracts, innovative delivery.